Pharmaceutical Preparations · DE · CIK 1231457
GENELUX Corp develops next-generation oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers
Comparable business profile · signals at a glance
In the 90 days to Mar 25, 2026: 5 sold $43K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Smalling RalphHead of Regulatory | Sell | 240 | $2.51 | $602 |
| Mar 24, 2026 | Zindrick ThomasPresident and CEO | Sell | 3,582 | $2.42 | $9K |
| Mar 24, 2026 | Yu YongSVP, Clinical Development | Sell | 906 | $2.42 | $2K |
| Mar 24, 2026 | Cappello JosephChief Technical Officer | Sell | 906 | $2.42 | $2K |
| Mar 24, 2026 | Smalling RalphHead of Regulatory | Sell | 345 | $2.42 | $835 |
| Mar 2, 2026 | Thomas JohnDirector | Sell | 10,000 | $2.90 | $29K |
| Dec 5, 2025 | Smalling RalphHead of Regulatory | Sell | 165 | $4.69 | $774 |
| Dec 1, 2025 | Thomas JohnDirector | Sell | 10,000 | $5.00 | $50K |
| Nov 17, 2025 | Zindrick ThomasPresident and CEO | Sell | 4,509 | $5.37 | $24K |
| Nov 17, 2025 | Yu YongSVP, Clinical Development | Sell | 973 | $5.37 | $5K |
| Nov 17, 2025 | Cappello JosephChief Technical Officer | Sell | 973 | $5.37 | $5K |
| Nov 17, 2025 | Smalling RalphHead of Regulatory | Sell | 343 | $5.37 | $2K |
| Sep 3, 2025 | Smalling RalphHead of Regulatory | Sell | 580 | $3.36 | $2K |
| Aug 21, 2025 | Zindrick ThomasPresident and CEO | Sell | 12,673 | $3.33 | $42K |
| Aug 21, 2025 | Yu YongSVP, Clinical Development | Sell | 3,219 | $3.36 | $11K |
| Aug 21, 2025 | Cappello JosephChief Technical Officer | Sell | 1,463 | $3.36 | $5K |
| Aug 21, 2025 | Cappello JosephChief Technical Officer | Sell | 1,270 | $3.33 | $4K |
| Aug 21, 2025 | Smalling RalphHead of Regulatory | Sell | 1,244 | $3.36 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.